Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:22 PM
Ignite Modification Date: 2025-12-25 @ 12:58 PM
NCT ID: NCT05370495
Description: Complies with clinicaltrials.gov definitions
Frequency Threshold: 1
Time Frame: 60 days
Study: NCT05370495
Study Brief: Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
SY-201 Ophthalmic Solution 2.0% SY-201 Ophthalmic Solution 2.0%: SY-201 Ophthalmic Solution 2.0% 0 None 0 49 8 49 View
SY-201 Ophthalmic Solution 1.0% SY-201 Ophthalmic Solution 1.0%: SY-201 Ophthalmic Solution 1.0% 0 None 0 51 3 51 View
SY-201 Ophthalmic Solution 0.5% SY-201 Ophthalmic Solution 0.5%: SY-201 Ophthalmic Solution 0.5% 0 None 0 50 4 50 View
SY-201 Ophthalmic Solution Vehicle SY-201 Ophthalmic Solution Vehicle: SY-201 Ophthalmic Solution Vehicle 0 None 0 48 4 48 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Eye Disorders SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (25.0) View
Instillation site irritation SYSTEMATIC_ASSESSMENT General disorders MedDRA (25.0) View